NUVALENT A RSS Feed | Nachrichten - www.finanzen.netwww.finanzen.net bietet Finanznachrichten zum weltweiten BörsengeschehenFinanzenhttps://www.finanzen.netde-definanzen.net GmbHTue, 28 Apr 2026 20:01:36 +0200https://images.finanzen.net/images/finanzen_net_neu.gifNUVALENT A RSS Feed | Nachrichten - www.finanzen.nethttps://www.finanzen.netNuvalent A gab Ergebnis zum abgelaufenen Quartal bekanntSun, 01 Mar 2026 06:35:06 +0100https://www.finanzen.net/nachricht/aktien/nuvalent-a-gab-ergebnis-zum-abgelaufenen-quartal-bekannt-15525983Nuvalent A lud am 26.02.2026 zur turnusmäßigen Finanzkonferenz und hat dort das Zahlenwerk zum jüngsten Quartal veröffentlicht, das am 31.12.2025 endete.Es wurde ein Verlust je Aktie in Höhe von 1,58 USD vermeldet. ...

]]>https://www.finanzen.net/nachricht/aktien/nuvalent-a-gab-ergebnis-zum-abgelaufenen-quartal-bekannt-15525983Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 MilestonesMon, 12 Jan 2026 12:30:00 +0100https://www.finanzen.net/nachricht/aktien/nuvalent-announces-ontarget-2026-operating-plan-progress-and-outlines-key-anticipated-2026-milestones-15408787

FDA accepted NDA for zidesamtinib for the treatment of TKI pre-treated patients with advanced ROS1-positive NSCLC; PDUFA target action date of September 18, 2026

]]>https://www.finanzen.net/nachricht/aktien/nuvalent-announces-ontarget-2026-operating-plan-progress-and-outlines-key-anticipated-2026-milestones-15408787Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare ConferenceMon, 22 Dec 2025 12:30:00 +0100https://www.finanzen.net/nachricht/aktien/nuvalent-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-15374253

CAMBRIDGE, Mass., Dec. 22, 2025 /PRNewswire/ -- Nuvalent, ...

]]>https://www.finanzen.net/nachricht/aktien/nuvalent-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-15374253Nuvalent Appoints Ron Squarer to Board of DirectorsWed, 10 Dec 2025 22:01:00 +0100https://www.finanzen.net/nachricht/aktien/nuvalent-appoints-ron-squarer-to-board-of-directors-15350520

CAMBRIDGE, Mass., Dec. 10, 2025 /PRNewswire/ -- Nuvalent, ...

]]>https://www.finanzen.net/nachricht/aktien/nuvalent-appoints-ron-squarer-to-board-of-directors-15350520Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare ConferenceWed, 26 Nov 2025 12:30:00 +0100https://www.finanzen.net/nachricht/aktien/nuvalent-to-participate-in-the-piper-sandler-37th-annual-healthcare-conference-15314703

CAMBRIDGE, Mass., Nov. 26, 2025 /PRNewswire/ -- Nuvalent, ...

]]>https://www.finanzen.net/nachricht/aktien/nuvalent-to-participate-in-the-piper-sandler-37th-annual-healthcare-conference-15314703Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLCWed, 19 Nov 2025 22:19:00 +0100https://www.finanzen.net/nachricht/aktien/nuvalent-announces-fda-acceptance-of-new-drug-application-for-zidesamtinib-for-the-treatment-of-tki-pre-treated-patients-with-advanced-ros1-positive-nsclc-15293552

NDA based on data from global ARROS-1 Phase 1/2 clinical trial

FDA assigns PDUFA target action date of September ...

]]>https://www.finanzen.net/nachricht/aktien/nuvalent-announces-fda-acceptance-of-new-drug-application-for-zidesamtinib-for-the-treatment-of-tki-pre-treated-patients-with-advanced-ros1-positive-nsclc-15293552Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLCMon, 17 Nov 2025 12:30:00 +0100https://www.finanzen.net/nachricht/aktien/nuvalent-announces-positive-topline-pivotal-data-from-alkove-1-clinical-trial-of-neladalkib-for-tki-pre-treated-patients-with-advanced-alk-positive-nsclc-15283853